oleogel-s10 Reduces Dressing Changes Burden and Associated Costs in Patients with Epidermolysis Bullosa

Introduction: Epidermolysis bullosa (EB) is a severe genetic disorder affecting epithelial integrity, primarily managed through frequent wound dressing changes. The EASE study demonstrated accelerated wound healing for Oleogel-S10 (birch triterpenes)* in EB (NCT03068780). This analysis evaluated the impact of Oleogel-S10 on dressing change frequen- cy, time spent and associated costs in patients requiring daily dressing changes at baseline. Methods: EASE enrolled 223 patients with dystrophic or junctional EB randomized to receive Oleogel-S10 (n=109) or control gel (n=114) with standard dressings. Here, a post hoc analysis focused on patients with daily dressing changes at baseline and, using historical data, time spent and saved on dressing changes was calculated. Results: Among the subset of patients with daily dressing changes at baseline (Oleogel-S10 n=47, control gel n=53), 35.6% receiving Oleogel-S10 experienced reduced requirements by Day 90, compared to 10.6% receiving control gel. Oleogel-S10 resulted in a mean reduction of 1.36±0.24 weekly dressing changes, significantly more than control gel (0.41±0.23 fewer; difference –0.95±0.33; p=0.005). This translated to almost three fewer dressing changes every two weeks for Oleogel-S10 versus nearly one change for the control gel. Estimated time saved on dressing changes per week for the daily change cohort was 10.9h for Oleogel-S10 (6.6h for patients and 4.4h for caregivers) versus 4.0h for the control gel (2.4h for patients and 1.6h for caregivers), with a trend to cost savings in favor of Oleogel-S10. Discussion: Oleogel-S10 significantly reduced dressing change fre- quency compared with control gel, potentially alleviating the burden of dressing changes and associated costs. CR-011 (RPT-006) Systemic Immune-inflammation Index (SII) as a Marker of Inflammation in Pyoderma Gangrenosum Bianca Cei, MD; Alessandra Michelucci, MD; Giammarco Granieri, MD; Serena Corraro, MD; Valentina Dini, PhD; Marco Romanelli, PhD Introduction: The systemic immune-inflammation index (SII) is a nov- el inflammation biomarker, increasingly applied in clinical practice. SII is calculated based on three parameters (platelet count, lymphocyte count, and neutrophil count in peripheral blood) and serves as an indicator of both inflammatory status and immune response. Pyoderma gangrenosum (PG) is a neutrophilic dermatosis characterized by a high inflammatory burden, with its etiology involving complex interactions among genetic, immune, and environmental factors. This study aims to investigate the SII levels in PG patients. Methods: A retrospective analysis was conducted on 16 patients diag- nosed with PG. Blood samples were collected from all patients. Lympho- cyte, neutrophil, monocyte, and platelet counts were measured as x10^3 cells/µL, and the SII was calculated using the formula: (platelet count x neutrophil count) / lymphocyte count. Results: The population includes 16 patients: 11 females (68.75%) and 5 males (31.25%), the average age is 59,68 with a standard deviation of 9. SII medium value is 6.689 with a standard deviation of 500.555. Discussion: SII values in patients with PG were higher than those typically observed in other chronic inflammatory skin diseases. The con- sistently elevated SII levels in PG highlight the potential for establishing a clinical cut-off value, which could aid in monitoring disease progression and tailoring treatment strategies. Further studies with larger cohorts are warranted to validate these results and determine a precise SII threshold for clinical application.